Stockhub

CrystalGenomics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 September 2022

  • curprev 07:5807:58, 22 September 2022 95.149.241.133 talk 1,162 bytes +1,162 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for..."
Retrieved from "https://stockhub.co/research/CrystalGenomics,_Inc."